GB VIRUS C INFECTION OF MACAQUES: AN HIV VACCINE MODEL

猕猴的 GB 病毒 C 感染：HIV 疫苗模型

• 批准号: 7349792
• 负责人: David L Thomas
• 金额: $ 5.73万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349792
• 关键词: GB; VIRUS; INFECTION; MACAQUES; HIV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. An estimated 40 million persons are infected with HIV, which caused more than three million deaths in 2001 alone. Efforts to prevent HIV infection by vaccination have no been successful, in large part because of the limited efficacy of conventional vaccine constructs as well as concerns with the safety of live virus vectors. To overcome these limitations, we propose using GB virus C, a recently discovered flavivirus, as a recombinant vector for HIV vaccines. GBV-C has many features of an ideal recombinant vector including: Safety 9No known human disease is associated with this virus which causes persistent infection in ~2% of healthy blood donors and, although transmitted by transfusion, is not screened for in donations.); experimental models (Cell lines exist for GBV-C and an infectious clone has already been made. In addition, there is evidence that macaques, the most important animal model for HIV vaccine research, are permissive for GBV-C.); and immunogenicity (Strong cellular and humoral immune responses are expected since the virus infects humans for months/decades.). Thus, the purpose of this pilot grant is to conduct preliminary studies required for expanded work to develop GBV-C as a recombinant vector for HVI vaccines. Our initial aims are to confirm that rhesus macaques can be infected with GBV-C, to characterize the natural history of infection, and to provisionally examine tissue tropism.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。估计有4 000万人感染艾滋病毒，仅2001年一年就造成300多万人死亡。通过疫苗接种预防艾滋病毒感染的努力并未取得成功，这在很大程度上是因为传统疫苗结构的效力有限，以及对活病毒载体安全性的担忧。为了克服这些局限性，我们建议使用最近发现的一种黄病毒GB病毒C作为HIV疫苗的重组载体。GBV-C具有理想的重组载体的许多特点，包括：安全性9没有已知的人类疾病与该病毒相关，该病毒在约2%的健康献血者中引起持续感染，尽管通过输血传播，但在献血者中未进行筛查。实验模型(GBV-C的细胞系已经存在，并且已经制造出具有传染性的克隆。此外，有证据表明，作为艾滋病毒疫苗研究最重要的动物模型，猕猴对GBV-C是允许的。免疫原性（由于病毒感染人类数月/数十年，预计会产生强烈的细胞和体液免疫反应）。因此，这项试点赠款的目的是开展扩大工作所需的初步研究，以开发GBV-C作为艾滋病毒疫苗的重组载体。我们最初的目的是确认恒河猴可以感染GBV-C，描述感染的自然史，并暂时检查组织趋向性。